Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 608

Similar articles for PubMed (Select 18665911)

1.

Mesenchymal stem cells therapy exerts neuroprotection in a progressive animal model of Parkinson's disease.

Park HJ, Lee PH, Bang OY, Lee G, Ahn YH.

J Neurochem. 2008 Oct;107(1):141-51. doi: 10.1111/j.1471-4159.2008.05589.x. Epub 2008 Jul 28.

PMID:
18665911
2.

Neuroprotective effects of human mesenchymal stem cells on dopaminergic neurons through anti-inflammatory action.

Kim YJ, Park HJ, Lee G, Bang OY, Ahn YH, Joe E, Kim HO, Lee PH.

Glia. 2009 Jan 1;57(1):13-23. doi: 10.1002/glia.20731.

PMID:
18661552
4.

Rat mesenchymal stem cells increase tyrosine hydroxylase expression and dopamine content in ventral mesencephalic cells in vitro.

Jin GZ, Cho SJ, Choi EG, Lee YS, Yu XF, Choi KS, Yee ST, Jeon JT, Kim MO, Kong IK.

Cell Biol Int. 2008 Nov;32(11):1433-8. doi: 10.1016/j.cellbi.2008.08.014. Epub 2008 Aug 20.

PMID:
18778785
5.

Intravenous administration of mesenchymal stem cells exerts therapeutic effects on parkinsonian model of rats: focusing on neuroprotective effects of stromal cell-derived factor-1alpha.

Wang F, Yasuhara T, Shingo T, Kameda M, Tajiri N, Yuan WJ, Kondo A, Kadota T, Baba T, Tayra JT, Kikuchi Y, Miyoshi Y, Date I.

BMC Neurosci. 2010 Apr 26;11:52. doi: 10.1186/1471-2202-11-52.

6.

Identification and kainic acid-induced up-regulation of low-affinity p75 neurotrophin receptor (p75NTR) in the nigral dopamine neurons of adult rats.

Wang YQ, Bian GL, Bai Y, Cao R, Chen LW.

Neurochem Int. 2008 Sep;53(3-4):56-62. doi: 10.1016/j.neuint.2008.06.007. Epub 2008 Jun 28.

PMID:
18639597
7.
8.

Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons.

Porritt MJ, Batchelor PE, Howells DW.

Exp Neurol. 2005 Mar;192(1):226-34.

PMID:
15698637
9.

KDI tripeptide of gamma1 laminin protects rat dopaminergic neurons from 6-OHDA induced toxicity.

Väänänen AJ, Rauhala P, Tuominen RK, Liesi P.

J Neurosci Res. 2006 Aug 15;84(3):655-65.

PMID:
16810683
10.

Neuroprotective effects of Astragaloside IV in 6-hydroxydopamine-treated primary nigral cell culture.

Chan WS, Durairajan SS, Lu JH, Wang Y, Xie LX, Kum WF, Koo I, Yung KK, Li M.

Neurochem Int. 2009 Nov;55(6):414-22. doi: 10.1016/j.neuint.2009.04.012. Epub 2009 May 4.

PMID:
19409437
11.

Proteasome inhibitor MG-132 induces dopaminergic degeneration in cell culture and animal models.

Sun F, Anantharam V, Zhang D, Latchoumycandane C, Kanthasamy A, Kanthasamy AG.

Neurotoxicology. 2006 Sep;27(5):807-15. Epub 2006 Jun 29.

PMID:
16870259
12.

Multiple neurogenic and neurorescue effects of human mesenchymal stem cell after transplantation in an experimental model of Parkinson's disease.

Cova L, Armentero MT, Zennaro E, Calzarossa C, Bossolasco P, Busca G, Lambertenghi Deliliers G, Polli E, Nappi G, Silani V, Blandini F.

Brain Res. 2010 Jan 22;1311:12-27. doi: 10.1016/j.brainres.2009.11.041. Epub 2009 Nov 26.

PMID:
19945443
13.

Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.

Chaturvedi RK, Shukla S, Seth K, Chauhan S, Sinha C, Shukla Y, Agrawal AK.

Neurobiol Dis. 2006 May;22(2):421-34. Epub 2006 Feb 9.

PMID:
16480889
14.

Reversal of dopaminergic degeneration in a parkinsonian rat following micrografting of human bone marrow-derived neural progenitors.

Glavaski-Joksimovic A, Virag T, Chang QA, West NC, Mangatu TA, McGrogan MP, Dugich-Djordjevic M, Bohn MC.

Cell Transplant. 2009;18(7):801-14. doi: 10.3727/096368909X470801. Epub 2009 Sep 28.

PMID:
19796495
15.

Environmental cue-dependent dopaminergic neuronal differentiation and functional effect of grafted neuroepithelial stem cells in parkinsonian brain.

Mine Y, Hayashi T, Yamada M, Okano H, Kawase T.

Neurosurgery. 2009 Oct;65(4):741-53; discussion 753. doi: 10.1227/01.NEU.0000351281.45986.76. Erratum in: Neurosurgery. 2009 Dec;65(6):1062.

PMID:
19834380
16.

Intranigral transplantation of epigenetically induced BDNF-secreting human mesenchymal stem cells: implications for cell-based therapies in Parkinson's disease.

Somoza R, Juri C, Baes M, Wyneken U, Rubio FJ.

Biol Blood Marrow Transplant. 2010 Nov;16(11):1530-40. doi: 10.1016/j.bbmt.2010.06.006. Epub 2010 Jun 10.

17.

Long-term efficacy and safety of human umbilical cord mesenchymal stromal cells in rotenone-induced hemiparkinsonian rats.

Xiong N, Cao X, Zhang Z, Huang J, Chen C, Zhang Z, Jia M, Xiong J, Liang Z, Sun S, Lin Z, Wang T.

Biol Blood Marrow Transplant. 2010 Nov;16(11):1519-29. doi: 10.1016/j.bbmt.2010.06.004. Epub 2010 Jun 10.

18.

Embryonic stem cell-derived L1 overexpressing neural aggregates enhance recovery in Parkinsonian mice.

Cui YF, Hargus G, Xu JC, Schmid JS, Shen YQ, Glatzel M, Schachner M, Bernreuther C.

Brain. 2010 Jan;133(Pt 1):189-204. doi: 10.1093/brain/awp290. Epub 2009 Dec 7.

19.

The influence of the subthalamic nucleus upon the damage to the dopamine system following lesions of globus pallidus in rats.

Wright AK, Arbuthnott GW.

Eur J Neurosci. 2007 Aug;26(3):642-8. Epub 2007 Jul 18.

PMID:
17634067
20.

Glial cell line-derived neurotrophic factor-secreting genetically modified human bone marrow-derived mesenchymal stem cells promote recovery in a rat model of Parkinson's disease.

Glavaski-Joksimovic A, Virag T, Mangatu TA, McGrogan M, Wang XS, Bohn MC.

J Neurosci Res. 2010 Sep;88(12):2669-81. doi: 10.1002/jnr.22435.

PMID:
20544825
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk